Crinetics Approach

News Releases

News Releases

July 17, 2018
Crinetics Pharmaceuticals Announces Pricing of Initial Public Offering

SAN DIEGO , July 17, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the

June 18, 2018
Crinetics Pharmaceuticals Appoints Alan Krasner, M.D., as Chief Medical Officer
SAN DIEGO – June 18, 2018  – Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of Alan S. Krasner, M.D.
March 13, 2018
Crinetics Pharmaceuticals Completes $63.5 Million Series B Financing
SAN DIEGO – March 13, 2018  – Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced it has completed a Series B financing which raised $63.5 million in new funds.
March 12, 2018
Crinetics Pharmaceuticals Announces Upcoming Presentations at ENDO 2018
SAN DIEGO – March 12, 2018  – Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced an oral presentation and two poster presentations relating to the company’s drug development candidates.
January 2, 2018
Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
SAN DIEGO – January 2, 2018  – Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced that Scott Struthers, Ph.D., founder and chief executive officer, will present at the 36th Annual J.P.